Moderna's Q3 Loss Widens Amidst Revenue Dip, R&D Spend Cuts

Ticker: MRNA · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Vaccines, mRNA Technology, Pharmaceuticals, Earnings Report, Net Loss, R&D Spending

Related Tickers: MRNA, PFE, BNTX, GSK

TL;DR

**Moderna's Q3 results are a stark reminder that the COVID vaccine boom is over, and their future hinges on new product launches and pipeline execution, which is a massive gamble.**

AI Summary

Moderna, Inc. (MRNA) reported a significant net loss of $200 million for the three months ended September 30, 2025, a substantial decline from a net income of $13 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $1,996 million, compared to a net loss of $2,441 million in the prior year. Total revenue decreased to $1,016 million for the quarter, down from $1,862 million year-over-year, primarily driven by a drop in net product sales to $973 million from $1,820 million. Research and development expenses also saw a reduction, falling to $801 million for the quarter from $1,137 million in Q3 2024, and to $2,357 million for the nine months from $3,421 million. The company introduced a new COVID vaccine, mNEXSPIKE, alongside its existing Spikevax and RSV vaccine mRESVIA, and is advancing a pipeline of 30 development candidates, with 37 in clinical studies. Cash and cash equivalents decreased from $1,927 million at December 31, 2024, to $1,132 million at September 30, 2025, reflecting net cash used in operating activities of $2,803 million for the nine-month period.

Why It Matters

Moderna's widening net loss and declining revenue signal a challenging post-pandemic landscape for the mRNA pioneer, impacting investor confidence and potentially its ability to fund its extensive pipeline. The introduction of mNEXSPIKE and mRESVIA is crucial for diversifying revenue beyond Spikevax, but their market penetration will determine future profitability. For employees, this could mean increased pressure on R&D efficiency and commercialization efforts. Customers will benefit from new vaccine options, but the company's financial health affects its long-term innovation capacity. Competitively, this performance puts Moderna under scrutiny as other pharmaceutical giants vie for market share in respiratory vaccines, making efficient pipeline execution paramount.

Risk Assessment

Risk Level: high — The company reported a net loss of $200 million for Q3 2025 and a nine-month net loss of $1,996 million, indicating significant unprofitability. Net product sales decreased substantially from $1,820 million in Q3 2024 to $973 million in Q3 2025, highlighting a sharp decline in core revenue. Cash and cash equivalents also dropped from $1,927 million at December 31, 2024, to $1,132 million at September 30, 2025, reflecting a net cash outflow of $2,803 million from operating activities, which raises concerns about liquidity and sustained operations without significant new revenue streams.

Analyst Insight

Investors should exercise caution and closely monitor the commercial performance of mRESVIA and mNEXSPIKE, as well as key pipeline milestones. Given the significant net losses and declining cash, a wait-and-see approach is advisable until there's clear evidence of successful market penetration for new products and a path to profitability.

Financial Highlights

debt To Equity
0.30
revenue
$1,016M
operating Margin
-25.6%
total Assets
$12,135M
total Debt
$2,805M
net Income
-$200M
eps
-$0.51
gross Margin
78.7%
cash Position
$1,132M
revenue Growth
-45.4%

Revenue Breakdown

SegmentRevenueGrowth
Net product sales$973M-46.55%
Other revenue$43M+2.44%

Key Numbers

Key Players & Entities

FAQ

What were Moderna's net product sales for the third quarter of 2025?

Moderna's net product sales for the three months ended September 30, 2025, were $973 million, a decrease from $1,820 million in the same period of 2024.

Did Moderna report a profit or loss in Q3 2025?

Moderna reported a net loss of $200 million for the three months ended September 30, 2025, compared to a net income of $13 million in Q3 2024.

How much cash and cash equivalents did Moderna have as of September 30, 2025?

As of September 30, 2025, Moderna had $1,132 million in cash and cash equivalents, down from $1,927 million at December 31, 2024.

What is Moderna's strategic outlook regarding its product pipeline?

Moderna is advancing a diverse and extensive development pipeline of 30 development candidates across 40 development programs, with 37 currently in clinical studies, focusing on respiratory virus vaccines, latent and other virus vaccines, oncology therapeutics, and rare disease therapeutics.

What are the key risks highlighted in Moderna's 10-Q filing?

Key risks include the ability to drive use of commercial products, execute on R&D, compete in COVID and RSV markets, obtain regulatory approvals, and manage internal and external manufacturing costs, as detailed in the 'Special Note Regarding Forward-Looking Statements' and 'Risk Factors' sections.

How has Moderna's research and development spending changed?

Research and development expenses decreased to $801 million for the three months ended September 30, 2025, from $1,137 million in the prior year period, and to $2,357 million for the nine months from $3,421 million.

What new products has Moderna introduced?

Moderna currently has three commercial products: Spikevax (original COVID vaccine), mRESVIA (RSV vaccine), and mNEXSPIKE (new COVID vaccine).

What is the impact of seasonal fluctuations on Moderna's sales?

Moderna anticipates seasonal fluctuations in demand for its COVID and RSV vaccines, with higher sales expected during the fall and winter seasons, which could influence future financial results.

How many shares of Moderna common stock were outstanding as of October 31, 2025?

As of October 31, 2025, there were 390,679,512 shares of Moderna's common stock, par value $0.0001 per share, outstanding.

What is Moderna's approach to intellectual property?

Moderna aims to obtain and maintain regulatory approval of its product candidates across its portfolio and establish and maintain protection for intellectual property rights covering its commercial products, product candidates, and technology, while also addressing pending legal proceedings related to its intellectual property.

Risk Factors

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Moderna operates in the vaccine and therapeutics market, which is highly competitive and influenced by public health needs, scientific advancements, and government policies. The post-pandemic landscape sees a shift in demand for COVID-19 vaccines, requiring companies to diversify their product portfolios and focus on next-generation innovations.

Regulatory Implications

Moderna's business is heavily reliant on regulatory approvals from bodies like the FDA. Any delays, rejections, or stringent post-market requirements for its existing or pipeline products could severely impact revenue and profitability. The company must also navigate evolving global health regulations and compliance standards.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Net product sales
Revenue generated from the sale of the company's pharmaceutical and biotechnology products. (Key indicator of commercial success for Moderna's vaccines and therapeutics.)
Research and development expenses
Costs incurred in the process of discovering, developing, and testing new drugs and vaccines. (Reflects Moderna's investment in future growth and pipeline advancement.)
Cash and cash equivalents
Highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Measures the company's immediate liquidity and ability to meet short-term obligations.)
Net cash used in operating activities
The net amount of cash used by a company's normal business operations over a period. (Indicates the cash burn rate of the company's core business.)
Diluted Net Loss Per Share
The net loss per share after accounting for all dilutive potential common shares, such as stock options and convertible securities. (Represents the per-share impact of the company's losses on shareholders.)
Deferred revenue
Revenue that has been received by the company but not yet earned, typically from advance payments for products or services to be delivered in the future. (Can indicate future revenue streams, but also obligations to deliver.)

Year-Over-Year Comparison

Moderna's Q3 2025 results show a significant deterioration compared to Q3 2024. Total revenue plummeted by 45.4% to $1,016M from $1,862M, driven by a 46.6% drop in net product sales. This revenue decline, coupled with sustained operating expenses, resulted in a net loss of $200M, a stark contrast to the $13M net income reported in the prior year. While R&D expenses were reduced, the company's cash position weakened considerably, with cash and cash equivalents down by $795M year-over-year, reflecting a substantial operating cash burn.

Filing Stats: 4,607 words · 18 min read · ~15 pages · Grade level 18.6 · Accepted 2025-11-06 16:05:25

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Comprehensive Income ( Loss ) for the three and nine months ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 8 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 10 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 29

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 40

Controls and Procedures

Item 4. Controls and Procedures 40 PART II. Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 5. Other Information 41

Exhibits

Item 6. Exhibits 42

SIGNATURES

SIGNATURES 43 Table of Contents

Financial Statements

Item 1. Financial Statements MODERNA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in millions, except per share data) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 1,132 $ 1,927 Investments 3,372 5,098 Accounts receivable, net 1,046 358 Inventory 332 117 Prepaid expenses and other current assets 716 599 Total current assets 6,598 8,099 Investments, non-current 2,143 2,494 Property, plant and equipment, net 2,126 2,196 Right-of-use assets, operating leases 738 759 Other non-current assets 530 594 Total assets $ 12,135 $ 14,142 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 267 $ 405 Accrued liabilities 1,178 1,427 Deferred revenue 163 153 Other current liabilities 73 221 Total current liabilities 1,681 2,206 Deferred revenue, non-current 157 58 Operating lease liabilities, non-current 660 671 Financing lease liabilities, non-current 26 39 Other non-current liabilities 281 267 Total liabilities 2,805 3,241 Commitments and contingencies ( Note 11 ) Stockholders' equity: Preferred stock, par value $ 0.0001 ; 162 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued or outstanding at September 30, 2025 and December 31, 2024 — — Common stock, par value $ 0.0001 ; 1,600 shares authorized as of September 30, 2025 and December 31, 2024; 391 and 386 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively — — Additional paid-in capital 1,254 866 Accumulated other comprehensive income (loss) 27 ( 10 ) Retained earnings 8,049 10,045 Total stockholders' equity 9,330 10,901 Total liabilities and stockholders' equity $ 12,135 $ 14,142 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 Table of Contents MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in millions, except per share data) Three Months

View on Read The Filing